Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $17.25.

Several analysts have weighed in on the company. StockNews.com upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th. JMP Securities reiterated a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th.

Insider Transactions at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly purchased 45,000 shares of the business’s stock in a transaction on Wednesday, February 12th. The stock was acquired at an average price of $5.69 per share, with a total value of $256,050.00. Following the completion of the acquisition, the chief executive officer now owns 846,638 shares of the company’s stock, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at $26,000. GAMMA Investing LLC purchased a new position in shares of Enanta Pharmaceuticals during the first quarter valued at about $40,000. Tower Research Capital LLC TRC increased its holdings in shares of Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 2,274 shares during the last quarter. Intech Investment Management LLC bought a new stake in Enanta Pharmaceuticals in the 4th quarter worth approximately $58,000. Finally, Squarepoint Ops LLC bought a new position in shares of Enanta Pharmaceuticals during the 4th quarter valued at approximately $66,000. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Trading Up 0.9 %

ENTA stock opened at $4.50 on Friday. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $17.24. The firm has a market capitalization of $96.00 million, a P/E ratio of -0.91 and a beta of 0.69. The firm has a 50 day moving average of $6.33 and a 200-day moving average of $7.76.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. Sell-side analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.